CompletedPhase 1

Tau PET Imaging in Atypical Dementias

United States70 participantsStarted 2016-02

Plain-language summary

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Who can participate

Age range20 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must have primary progressive aphasia Exclusion Criteria: * Pregnancy * Breastfeeding * Receiving radiation clinically

What they're measuring

Tau levels in PPA participants

Timeframe: 2 years

Trial details

NCT IDNCT03283449

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-28

View on ClinicalTrials.gov More Primary Progressive Aphasia With Suspected Alzheimer's Disease trials